Skip to main content
Premium Trial:

Request an Annual Quote

Caliper Technologies, Pharmacopeia Added to Nasdaq Biotech Index

NEW YORK, May 14 – Caliper Technologies and Pharmacopeia will be among seven new companies included in the Nasdaq Biotechnology Index as of marketing opening May 21, Nasdaq announced on Monday. 

Companies included in the Index are evaluated semi-annually for minimum price, market value, and average daily share volume requirements.

Sixteen companies will be removed, including Lexicon Genetics. The Woodlands, Texas-based company on May 8 announced flat revenues first-quarter 2001 compared to the year-ago quarter.

Caliper, based in Mountain View, Calif., designs and manufactures lab-on-chip technologies. It had a market capitalization of $385 million at the time of selection.

Pharmacopeia of Princeton, NJ, has a drug discovery segment and recently merged its four software units into a single subsidiary called Accelrys. The company had a market capitalization of $23 million at the time of its selection.

The Nasdaq Biotechnology Index, which was started in 1993, increased 23 percent in 2000.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.